| SC 13G | 2022-02-14 | JANUS HENDERSON GROUP PLC | Aligos Therapeutics, Inc. | 2,419,613 | 5.7% | EDGAR |
| SC 13G/A | 2022-02-10 | WELLINGTON MANAGEMENT GROUP LLP | Aligos Therapeutics, Inc. | 1,304,321 | 3.1% | EDGAR |
| SC 13G/A | 2022-02-10 | BLATT LAWRENCE | Aligos Therapeutics, Inc. | 2,509,377 | 6.2% | EDGAR |
| SC 13G/A | 2022-02-10 | Beigelman Leonid | Aligos Therapeutics, Inc. | 1,872,350 | 4.7% | EDGAR |
| SC 13G/A | 2022-02-04 | Wellington Biomedical Innovation Master Investors (Cayman) I L.P. | Aligos Therapeutics, Inc. | 1,206,191 | 2.8% | EDGAR |
| SC 13G/A | 2022-02-04 | WELLINGTON MANAGEMENT GROUP LLP | Aligos Therapeutics, Inc. | 3,561,971 | 8.4% | EDGAR |
| SC 13D/A | 2022-01-31 | Novo Holdings A/S | Aligos Therapeutics, Inc. | 1,950,000 | 4.9% | EDGAR |
| SC 13G | 2021-08-13 | Logos Global Management LP | Aligos Therapeutics, Inc. | 2,872,785 | 6.7% | EDGAR |
| SC 13D/A | 2021-06-21 | Novo Holdings A/S | Aligos Therapeutics, Inc. | 2,614,563 | 7.5% | EDGAR |
| SC 13D/A | 2021-06-21 | Versant Venture Capital VI, L.P. | Aligos Therapeutics, Inc. | 1,457,937 | 3.8% | EDGAR |
| SC 13D/A | 2021-05-03 | Versant Venture Capital VI, L.P. | Aligos Therapeutics, Inc. | 1,943,916 | 5.1% | EDGAR |
| SC 13G | 2021-02-16 | HILLHOUSE CAPITAL ADVISORS, LTD. | Aligos Therapeutics, Inc. | 2,165,064 | 5.7% | EDGAR |
| SC 13G | 2021-02-16 | ROCHE FINANCE LTD | Aligos Therapeutics, Inc. | 3,092,340 | 8.1% | EDGAR |
| SC 13G | 2021-02-11 | Beigelman Leonid | Aligos Therapeutics, Inc. | 1,797,350 | 5.1% | EDGAR |
| SC 13G | 2021-02-11 | BLATT LAWRENCE | Aligos Therapeutics, Inc. | 2,396,877 | 6.7% | EDGAR |
| SC 13G | 2021-01-11 | WELLINGTON MANAGEMENT GROUP LLP | Aligos Therapeutics, Inc. | 3,927,598 | 10.3% | EDGAR |
| SC 13D | 2020-10-30 | Versant Venture Capital VI, L.P. | Aligos Therapeutics, Inc. | 2,429,895 | 7.2% | EDGAR |
| SC 13G | 2020-10-28 | Vivo Capital VIII, LLC | Aligos Therapeutics, Inc. | 3,547,030 | 10.5% | EDGAR |
| SC 13D | 2020-10-22 | Novo Holdings A/S | Aligos Therapeutics, Inc. | 2,614,563 | 7.7% | EDGAR |
| SC 13G | 2020-10-22 | Wellington Biomedical Innovation Master Investors (Cayman) I L.P. | Aligos Therapeutics, Inc. | 1,906,191 | 5.3% | EDGAR |